Fig. 3From: Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cellsOverview of measurements of LDH values as a function of culture time a: LDH values for 0–250 μg / ml ranibizumab (Lucentis®) b: LDH values for 0–250 μg/ml bevacizumab (Avastin®); c: LDH values for ranibizumab (Lucentis®) or bevacizumab (Avastin®) after background correction with 0 μg/ml control groupBack to article page